Virpax Pharmaceuticals Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 317.2%.

Top 18 shareholders own 9.44% of the company

Ownership	Name	Shares	Current Value	Change %	Portfolio %
5.59%	Virpax Pharmaceuticals, LLC	273,043	US$167.7k	0%	no data
1.17%	Garden State Investment Advisory Services, LLC	57,300	US$35.2k	0%	0.01%
0.64%	Citadel Advisors LLC	31,382	US$19.3k	0%	no data
0.57%	Geode Capital Management, LLC	27,971	US$17.2k	338%	no data
0.52%	Anthony Mack	25,255	US$15.5k	0%	no data
0.42%	UBS Asset Management AG	20,435	US$12.6k	1,780%	no data
0.26%	Two Sigma Securities, LLC, Asset Management Arm	12,522	US$7.7k	0%	no data
0.14%	The Vanguard Group, Inc.	6,629	US$4.1k	0%	no data
0.079%	Tower Research Capital Europe Limited	3,837	US$2.4k	22%	no data
0.018%	Jerrold Sendrow	900	US$552.7	0%	no data
0.016%	Eric Floyd	800	US$491.4	0%	no data
0.016%	Jeffrey Gudin	758	US$465.6	0%	no data
0.0083%	Gerald Bruce	404	US$248.3	0%	no data
0.0021%	Thanigavelan Jambulingam	100	US$61.5	0%	no data
0.001%	Signature Resources Capital Management, LLC	50	US$30.6	0%	no data
0.00076%	Bank of America Corporation, Asset Management Arm	37	US$22.8	429%	no data
0.00031%	Morgan Stanley, Investment Banking and Brokerage Investments	15	US$9.3	0%	no data
0.0002%	Hantz Financial Services, Inc., Asset Management Arm	10	US$6.0	0%	no data